

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 61472

Manuscript Type: CASE REPORT

Combined immune checkpoint inhibitors of CTLA4 and PD-1 for hepatic melanoma of unknown primary origin: A case report

Chen AC *et al.* Immunotherapy for hepatic melanoma of unknown primary

An-Che Cheng, Yi-Jia Lin, Sung-Hua Chiu, Yu-Lueng Shih

Abstract

BACKGROUND

Melanoma is uncommonly found in lymph nodes, subcutaneous tissue, or visceral

Match Overview

1	Internet 34 words crawled on 20-Aug-2020 www.tandfonline.com	1%
2	Internet 18 words crawled on 06-Jan-2021 www.ncbi.nlm.nih.gov	1%
3	Internet 16 words crawled on 19-Jan-2021 pesquisa.bvsalud.org	1%
4	Internet 15 words crawled on 13-Apr-2020 ascopubs.org	1%

国内版

国际版

Combined Immune Checkpoint Inhibitors of CTLA4 and PD-1 for He



ALL

IMAGES

VIDEOS

21,900 Results

Any time ▾

[\(PDF\) Case report: reinitiating pembrolizumab treatment ...](#)

https://www.researchgate.net/publication/332639980_Case_report_reinitiating...

Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and programmed death-1 (PD-1)/ligand are increasingly used to treat several types of cancer.

[Complete intracranial response to talimogene laherparepvec ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887256>

Keywords: **Melanoma**, Brain metastases, Talimogene laherparepvec, T-Vec, **Checkpoint inhibitors**, Anti-**PD1**, Anti-**CTLA4**, Nivolumab, Ipilimumab, Pembrolizumab Background Immunotherapy (IO) has changed the clinical landscape for patients diagnosed with metastatic **melanoma**, with **checkpoint inhibition** driving the dramatic improvement in clinical ...

Cited by: 11

Author: Zoë Blake, Douglas K. Marks, Robyn D. ...

Publish Year: 2018

[Immune evasion mechanisms and immune checkpoint ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665072>

Aug 31, 2017 · Suppression of the cell-mediated **immune** response can occur as a result of upregulated inhibitory receptors, such as **PD-1** and PD-L1, on tumor and **immune** cells. PD-L1 is expressed on tumor and **immune** cells in both virus-positive and virus-negative MCC tumors, providing a rationale for investigating **checkpoint inhibitors** targeting **PD-1** or PD-L1 in ...

Cited by: 20

Author: Dirk Schadendorf, Paul Nghiem, Shailend...

Publish Year: 2017

[Severe combined cardiac and neuromuscular toxicity from ...](#)

<https://cardiooncologyjournal.biomedcentral.com/...> ▾



ALL

IMAGES

VIDEOS

16,400 Results

Any time ▾

Durable Complete Response in a Melanoma Patient With ...

<https://pubmed.ncbi.nlm.nih.gov/33262949>

Monoclonal antibodies blocking **PD-1** and **CTLA-4** immunological checkpoints lead to durable tumor responses in a considerable number of advanced **melanoma** patients. Besides their anti-neoplastic efficacy, these **immune** checkpoint **inhibitors** cause a wide range of **immune**-related adverse events (irAEs), often enforcing an early discontinuation of therapy.

Author: Johanna Matull, Elisabeth Livingsto... **Publish Year:** 2020

Biologic subtypes of melanoma predict survival benefit of ...

<https://jitc.bmj.com/content/9/1/e001642> ▾

Purpose Anti-programmed cell death protein 1 (**PD1**)±anti-cytotoxic T-lymphocyte associated protein 4 (**CTLA4**) **immune** checkpoint **inhibitors** (ICIs) are standard therapeutic options for metastatic **melanoma**. We assessed whether biologic subtype according to **primary** tumor type or genomic subtype can function as predictive biomarkers for anti-**PD1**±anti-**CTLA4** ICI in patients with advanced **melanoma** ...

Severe combined cardiac and neuromuscular toxicity from ...

<https://cardiooncologyjournal.biomedcentral.com/...> ▾

Sep 23, 2020 · **Immune** checkpoint **inhibitors** (ICI), including antibodies against cytotoxic T-lymphocyte associated antigen-4 (**CTLA-4**), programmed cell death-1 (**PD-1**), and programmed-death-ligand-1 (PD-L1). function to help the body overcome potential barriers to the recognition

Search Tools

Turn off Hover Translation (关闭取词)

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

18,000 Results

Any time ▾

Open links in new tab



Durable Complete Response in a Melanoma Patient With ...

<https://pubmed.ncbi.nlm.nih.gov/33262949>

Monoclonal antibodies blocking **PD-1** and **CTLA-4** immunological checkpoints lead to durable tumor responses in a considerable number of advanced **melanoma** patients. Besides their anti-neoplastic efficacy, these **immune** checkpoint **inhibitors** cause a wide range of **immune**-related adverse events (irAEs), often enforcing an early discontinuation of therapy.

Author: Johanna Matull, Elisabeth Livingsto... **Publish Year:** 2020

Biologic subtypes of melanoma predict survival benefit of ...

<https://jitc.bmj.com/content/9/1/e001642> ▾

Jan 01, 2021 · Purpose Anti-programmed cell death protein 1 (**PD1**)±anti-cytotoxic T-lymphocyte associated protein 4 (**CTLA4**) **immune** checkpoint **inhibitors** (ICIs) are standard therapeutic options for metastatic **melanoma**. We assessed whether biologic subtype according to **primary** tumor type or genomic subtype can function as predictive biomarkers for anti-**PD1**±anti-**CTLA4** ICI in patients with advanced **melanoma** ...

Frontiers | Durable Complete Response in a Melanoma ...

<https://www.frontiersin.org/articles/10.3389/fonc.2020.592609> ▾

Nov 11, 2020 · **Monoclonal antibodies** blocking PD-1 and CTLA-4 immunological checkpoints lead to durable tumor responses in a considerable number of advanced melanoma patients. Besides their anti-neoplastic efficacy, these immune checkpoint inhibitors cause a wide range of immune-related adverse events (irAEs), often enforcing an early discontinuation of therapy.

Author: Johanna Matull, Elisabeth Livingsto... **Publish Year:** 2020

Myocarditis in Cynomolgus Monkeys Following Treatment with ...

<https://clincancerres.aacrjournals.org/content/25/15/4735> ▾

Aug 01, 2019 · Purpose: **Immune** checkpoint **inhibitors** (ICI) targeting **PD1**, **PDL1**, or **CTLA4** are associated with **immune**-related adverse events (irAE) in multiple organ systems including myocarditis. The pathogenesis and early diagnostic markers for ICI-induced myocarditis are poorly understood, and there is currently a lack of laboratory animal model to enhance our ...

Cited by: 11

Author: Changhua Ji, Marc D. Roy, Jonathan Go...

Publish Year: 2019